cilostazol has been researched along with Colitis in 3 studies
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The phosphodiesterase-3 inhibitor, cilostazol has been recently shown to protect against chemically induced colitis in animal models." | 7.96 | Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway. ( Elhassanny, AEM; Elshazly, SM; Mahmoud, NM, 2020) |
| "We previously reported the anti-inflammatory effects of cilostazol, a selective inhibitor of phosphodiesterase 3, and two antioxidants, enzymatically modified isoquercitrin and α-lipoic acid in a dextran sodium sulphate-induced colitis mouse model." | 7.85 | Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. ( Hayashi, SM; Hippo, Y; Kangawa, Y; Kihara, T; Maruyama, K; Nakamura, M; Ochiai, M; Okamoto, M; Shibutani, M; Yoshida, T, 2017) |
| "The phosphodiesterase-3 inhibitor, cilostazol has been recently shown to protect against chemically induced colitis in animal models." | 3.96 | Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway. ( Elhassanny, AEM; Elshazly, SM; Mahmoud, NM, 2020) |
| "We previously reported the anti-inflammatory effects of cilostazol, a selective inhibitor of phosphodiesterase 3, and two antioxidants, enzymatically modified isoquercitrin and α-lipoic acid in a dextran sodium sulphate-induced colitis mouse model." | 3.85 | Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. ( Hayashi, SM; Hippo, Y; Kangawa, Y; Kihara, T; Maruyama, K; Nakamura, M; Ochiai, M; Okamoto, M; Shibutani, M; Yoshida, T, 2017) |
| " We examined the inhibitory effects of a selective phosphodiesterase-3 inhibitor, cilostazol (CZ), and two antioxidants, enzymatically modified isoquercitrin (EMIQ) and α-lipoic acid (ALA), against dextran sulphate sodium (DSS)-induced colitis." | 3.85 | Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and α-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice. ( Abe, H; Hayashi, SM; Kangawa, Y; Kihara, T; Miyashita, T; Nakamura, M; Seto, Y; Shibutani, M; Yoshida, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Elshazly, SM | 1 |
| Elhassanny, AEM | 1 |
| Mahmoud, NM | 1 |
| Kangawa, Y | 2 |
| Yoshida, T | 2 |
| Maruyama, K | 1 |
| Okamoto, M | 1 |
| Kihara, T | 2 |
| Nakamura, M | 2 |
| Ochiai, M | 1 |
| Hippo, Y | 1 |
| Hayashi, SM | 2 |
| Shibutani, M | 2 |
| Abe, H | 1 |
| Seto, Y | 1 |
| Miyashita, T | 1 |
3 other studies available for cilostazol and Colitis
| Article | Year |
|---|---|
Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Cilostazol; Colitis; Colon; Cyclic AMP; Cytoprotecti | 2020 |
Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation.
Topics: Animals; Azoxymethane; Carcinogens; Cell Proliferation; Cilostazol; Colitis; Colonic Neoplasms; Enzy | 2017 |
Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and α-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cilostazol; Colitis; Dextran Sulfate; Disease Model | 2017 |